Buy Lorcaserin HCL powder (846589-98-8) hplc≥98% - Wisepowder
Chemical Base Information
Name Lorcaserin HCL
Chemical name (1R)-8-Chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine hydrochloride; R Lorcaserin hydrochloride;lorcaserin hydrochloride (APD-356);
Synonyms Lorcaserin hydrochloride; APD 356; APD-356; APD356; Belviq Xr; Lorqess.
Molecular Formula C11H15Cl2N
Molecular Weight 232.1525
Melting Point 212°C
InChI Key ITIHHRMYZPNGRC-QRPNPIFTSA-N
Appearance white crystalline powder
Half Life approximately 11 hours.
Solubility Soluble in DMSO
Storage Condition Dry, dark and at 0 – 4 C for short term (days to weeks) or -20 C for long term (months to years).
Application Lorcaserin HCL is a selective serotonin 2C agonist for forchronic weight management, to treating obesity.
Testing Document Available
03 Lorcaserin HCL (846589-98-8) General Description
Lorcaserin HCL is a selective serotonin 2C agonist labeled for chronic weight managementin adults who are obese (body mass index [BMI] ≥ 30 kg per m2) or who are overweight (BMI ≥ 27 kg per m2) with at least one weight-related comorbidity. Similar to other weight-loss medications, Lorcaserin HCL should be used in conjunction with diet and exercise. It suppresses appetite by activating the 5-HT2C receptors, which are types of serotonin receptors in a region of the brain (hypothalamus) that controls appetite. Lorcaserinaffects chemical signals in the brain that control appetite. Lorcaserin HCL works by helping you feel full with smaller meals. it is used together with diet and exercise to treat obesity.
Lorcaserin HCL is sometimes used to treat obesity that may be related to diabetes, highcholesterol, or high blood pressure. However, Lorcaserin HCL will not treat any underlyinghealth condition (such as heart disease, diabetes, high blood pressure).
04 Lorcaserin HCL (846589-98-8) History
Obesity is the second most common preventable cause of death, second only to tobaccouse. Evidence suggests that weight reduction substantially lowers the risk of related comorbidities and fosters their therapeutic. In June 2012, the US FDA approved lorcaserin forchronic weight management in adult patients who are characterized as overweight or obese and have at least one comorbid, weight-related condition. Lorcaserin (also known as APD356) is the first 5-HT2C agonist approved for chronic weight management since the withdrawal of the 5-HT2C agonist fenfluramine in 1997 due to rare cases of cardiac valvulopathy. It plays a big role in helping people lose weight in health and safety.